B of A Securities Maintains Buy on Vaxcyte, Lowers Price Target to $130

Benzinga Newsdesk www.benzinga.com Negative 67.8%

Neg 67.8% Neu 0% Pos 0%

B of A Securities analyst Jason Gerberry maintains Vaxcyte (NASDAQ:PCVX) with a Buy and lowers the price target from $133 to $130.